Alpha Wealth Funds’s Maravai LifeSciences MRVI Stock Holding History

Alpha Wealth Funds’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-72,000	Closed	-$207K	–	75
2026 Q1	$207K	Hold	72,000	–	–	0.14%	33
2025 Q4	$245K	Hold	72,000	–	–	0.15%	41
2025 Q3	$176K	Hold	72,000	–	–	0.13%	40
2025 Q2	$176K	Hold	72,000	–	–	0.15%	39
2025 Q1	$159K	Buy	72,000 +2,000	+3%	+$7.9K	0.16%	36
2024 Q4	$386K	Buy	+70,000	New	+$450K	0.37%	36

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.91B AUM 14.64% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

1WCM

12 West Capital Management New York $535M AUM 25.99% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

OAM

Ophir Asset Management Sydney, Australia $1.22B AUM 100.03% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

Alpha Wealth Funds's MRVI Position: Q2 2026 in Review

Alpha Wealth Funds sold out of Maravai LifeSciences (MRVI) in Q2 2026, closing a stake of 72,000 shares — an estimated $207K sold.

Alpha Wealth Funds first reported a position in MRVI in Q4 2024 and held it in 6 quarters. The position peaked at $386K in Q4 2024. 178 funds tracked by Wall St. Rank hold MRVI as of Q2 2026.

Alpha Wealth Funds reported no remaining Maravai LifeSciences position as of Q2 2026 after selling out during the quarter.
Alpha Wealth Funds sold 72,000 Maravai LifeSciences shares in Q2 2026, an estimated $207K.
Alpha Wealth Funds first reported a position in Maravai LifeSciences in Q4 2024 and held it in 6 quarters.
Alpha Wealth Funds's Maravai LifeSciences position peaked at $386K in Q4 2024.
178 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2026.

Based on Alpha Wealth Funds's 13F filing for Q2 2026, filed 11 Aug 2026.